Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Fastest Single-Cell Spatial Biology System
14 January 2022 - 12:05AM
Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology
Company®, today announced the commercial availability of the
PhenoCycler™-Fusion system, setting a new standard in spatial
biology for high-speed imaging of whole slides, at single-cell and
sub-cellular resolution.
The PhenoCycler-Fusion platform fuses the strengths of the
company’s automated, ultrahigh multiplex cycling platform,
PhenoCycler (previously branded as CODEX), and its high-speed
imaging platform, PhenoImager™ (previously branded as Phenoptics),
into an end-to-end, integrated workflow. The unprecedented speed of
its workflow enables researchers to image multiple biomarkers and
millions of cells across whole slides in just minutes, providing an
unbiased view of how cells spatially organize and interact to
influence disease outcomes.
A unique benefit of the system is its tunable workflow that
offers researchers the flexibility to run large panels for
hypothesis-free biomarker discovery and focused panels for
high-throughput biomarker validation, all on a single system. This
breakthrough capability simplifies the translation of spatial
biomarker signatures onto the PhenoImager HT, a high-throughput
platform that can process 300+ samples per week.
“The PhenoCycler-Fusion delivers on our vision of providing an
integrated solution to scale up spatial biology studies that
require larger panels, higher sample throughput and an unbiased
interrogation of every cell from a tissue sample.” said Brian
McKelligon, Chief Executive Officer of Akoya Biosciences.
In addition to its well-established protein biomarker assays,
the system will also be enabled with RNA detection to provide a
deeper, comprehensive view into tissue biology. To this end, Akoya
recently announced a partnership with Bio-Techne, to automate
RNAScope assays, a highly cited and proven standard in RNA imaging,
on the PhenoCycler-Fusion system. This multiomic workflow will also
complement a novel spatial transcriptomics chemistry, currently
being developed by Akoya, which will also be compatible with
PhenoCycler-Fusion.
“Spatial discovery is all about studying the rich diversity of
cell types, cellular neighborhoods and their interactions, across
the entirety of a tissue section.” said Garry Nolan, Ph.D., the
Rachford and Carlota A. Harris Professor in the Department of
Microbiology and Immunology at Stanford University School of
Medicine and a leading pioneer in the field of spatial biology.
“This can happen on a much larger scale if we can image whole
slides with a high-speed system like PhenoCycler-Fusion. The
throughput, flexibility, and compatibility with archived slides are
some of the reasons we decided to adopt the platform in our
lab.”
“We’ve been using the CODEX platform for studying the spatial
interactions of tumor and immune cells and how they behave in
response to immunotherapy” said Robert Schreiber, Ph.D., Professor
of Pathology and Immunology, Washington University, St. Louis and a
renowned expert in immuno-oncology. “With PhenoCycler-Fusion we can
now scale up to higher throughput studies with large cohorts of
samples and image entire slides in a rapid timeframe.”
The PhenoCycler-Fusion offers the following features:
- Single-cell and sub-cellular resolution, at a standard long
established by Akoya’s spatial phenotyping systems
- Ultrahigh plex detection of 100+ markers for deep spatial
phenotyping
- Rapid, unbiased mapping of every cell across entire tissue
sections, including archived FFPE (formalin-fixed,
paraffin-embedded) slides
- High-speed imaging that enables the processing of 100+ whole
slides per week.
- Multiomic detection of protein and RNA biomarkers
To underscore the powerful future of the integrated spatial
phenotyping portfolio, Akoya has also rebranded its existing
products – CODEX is now PhenoCycler, the Phenoptics workflow is
renamed as PhenoImager, and the Vectra Polaris instrument is the
PhenoImager HT.
For more information about PhenoCycler-Fusion, please visit
akoyabio.com/fusion.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research via its key platforms:
PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more
about Akoya, visit www.akoyabio.com.
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciencesinvestors@akoyabio.com
Media Contact:
Michelle LinnBioscribe, Inc.774-696-3803
michelle@bioscribe.com
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/14ae518b-2321-4fb1-96cb-a2f90a423c43https://www.globenewswire.com/NewsRoom/AttachmentNg/bef68b0b-4610-43d1-8ae7-14cd596cd1b4
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2023 to Apr 2024